香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Kindstar Globalgene Technology, Inc. 康聖環球基因技術有限公司 （於開曼群島註冊成立的有限公司） （股份代號：9960） 關連交易 收購華西康聖達40%股權 收購事項 董事會欣然宣佈，武漢康聖達（一家中國綜合實體）透過北交所公開掛牌程序成 功競得華西健康科技持有的華西康聖達（一家中國綜合實體）40%股權。於2025 年11月25日，武漢康聖達與華西健康科技訂立產權交易合同，據此，武漢康 聖達同意收購，而華西健康科技同意出售華西康聖達40%股權，對價為人民幣 12,396,000元。 上市規則之涵義 華西康聖達為一家中國綜合實體。截至本公告日期，轉讓方為華西康聖達的主 要股東，因此在附屬公司層面為本公司的關連人士。因此，收購事項構成本公 司的關連交易。根據上市規則第14A.101條，由於董事會已批准收購事項，而獨 立非執行董事已確認收購事項的條款屬公平合理，且收購事項按 ...

Core Points - Mialkos Tomasz Jakub increased his stake in Kangsheng Global (09960.HK) by purchasing 524,000 shares at an average price of HKD 1.2717 per share, totaling approximately HKD 666,400 [1] - Following this transaction, Mialkos Tomasz Jakub's total shareholding rose to 72.912 million shares, increasing his ownership percentage from 6.95% to 7.00% [1] Summary by Category Shareholding Activity - Mialkos Tomasz Jakub acquired 524,000 shares on November 19, 2025 [2] - The average purchase price was HKD 1.2717 per share [2] - The total investment for this acquisition was about HKD 666,400 [1] Ownership Changes - After the purchase, Mialkos Tomasz Jakub's total shares held reached 72.912 million [2] - His ownership percentage increased from 6.95% to 7.00% [1]

致：香港交易及結算所有限公司 公司名稱: 康聖環球基因技術有限公司 呈交日期: 2025年11月5日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09960 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.00025 | USD | | 500,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 2,000,000,000 | USD | | 0.00025 | USD | | 500,000 | 本月底法定/ ...

Core Insights - The article presents a ranking of 33 Hong Kong-listed medical service companies based on their stock price performance as of September 30, 2025, highlighting significant price increases and declines among these companies [1][2]. Group 1: Top Performers - The top performer is Brainstorm Cell Therapeutics (脑动极光-B) with a stock price of HKD 8.58, reflecting a remarkable increase of 166.46% [1]. - MediWound (麦迪卫康) ranks second with a stock price of HKD 1.23, showing a growth of 136.54% [1]. - Yonghe Medical (雍禾医疗) comes in third with a stock price of HKD 2.05, marking a rise of 127.78% [1]. Group 2: Notable Declines - The company with the largest decline is Yimeng Group (云康集团), with a stock price of HKD 1.28, experiencing a drop of 86.15% [1]. - Meizhong Jiahe (美中嘉和) follows with a stock price of HKD 3.20, down by 70.91% [1]. - Another significant decline is seen in Yimeng Sunshine (一昧阳光), which has a stock price of HKD 17.00, down by 76.06% [1]. Group 3: Market Capitalization - Fosun Pharma (复星医药) has the highest market capitalization at HKD 680.48 billion, with a stock price of HKD 25.78 [2]. - Far East Horizon (远东宏信) ranks second with a market cap of HKD 328.32 billion and a stock price of HKD 6.87 [2]. - Global Medical (环球医疗) holds a market cap of HKD 114.82 billion, with a stock price of HKD 6.07 [2].

Group 1 - The core point of the news is that Mialkos Tomasz Jakub increased his stake in Kangsheng Global (09960.HK) by purchasing 262,500 shares at an average price of HKD 1.5325 per share, resulting in a total investment of approximately HKD 402,300 [1][2] - Following this transaction, Mialkos Tomasz Jakub's total shareholding increased to 62,480,500 shares, raising his ownership percentage from 5.97% to 6.00% [1][2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康聖環球基因技術有限公司 呈交日期: 2025年10月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09960 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.00025 | USD | | 500,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 2,000,000,000 | USD | | 0.00025 | USD | | 500,000 | 本月底法定/註 ...

Definitions [Definitions](index=3&type=section&id=%E9%87%8A%E4%B9%89) This section provides definitions of key terms used throughout the report Company Information [Board of Directors and Committees](index=6&type=section&id=%E8%91%A3%E4%BA%8B%E4%BC%9A%E5%8F%8A%E5%A7%94%E5%91%98%E4%BC%9A) This section lists the company's Board of Directors (executive, non-executive, independent non-executive directors) and the composition of the Audit, Remuneration, and Nomination Committees - Board members include **Dr. Huang Shiang** (Chairman and CEO), **Mr. Tu Zanbing**, **Ms. Chai Haijie** as executive directors; **Mr. Huang Ruijin**, **Mr. Peng Wei**, **Ms. Huang Lu** as non-executive directors; and **Dr. Yao Shanglong**, **Dr. Xia Xinping**, **Mr. Gu Huaming** as independent non-executive directors[11](index=11&type=chunk) - The Audit Committee Chairman is **Dr. Xia Xinping**, the Remuneration Committee Chairman is **Mr. Gu Huaming**, and the Nomination Committee Chairman is **Dr. Huang Shiang**[11](index=11&type=chunk) [Corporate Administrative Information](index=6&type=section&id=%E5%85%AC%E5%8F%B8%E8%A1%8C%E6%94%BF%E4%BF%A1%E6%81%AF) This section provides key administrative and contact information, including the company secretary, authorized representatives, legal advisors, auditors, registered office, principal place of business, website, share registrar, and principal bankers - The company secretary is **Ms. Chai Haijie** and **Ms. Li Meiyi** (resigned on August 29, 2025), and authorized representatives are **Ms. Chai Haijie** and **Mr. Tu Zanbing** (appointed on August 29, 2025)[11](index=11&type=chunk) - The auditor is **Ernst & Young**, and Hong Kong legal counsel is Jingtian & Gongcheng LLP[11](index=11&type=chunk) - The company's website is www.kindstar.com.cn, and stock code is **9960**[12](index=12&type=chunk) Business Review and Outlook [Specialized Diagnostic Testing Business Remains Robust](index=8&type=section&id=%E4%B8%93%E7%A7%91%E7%89%B9%E6%A3%80%E4%B8%9A%E5%8A%A1%E4%BF%9D%E6%8C%81%E7%A8%B3%E5%81%A5) In H1 2025, the company optimized operations, strengthened its market position in six core specialized diagnostic testing areas like hematology, neurology, and oncology, and expanded its business through technological innovation and strategic M&A - Hematology diagnostic testing services added over **90** new hospital clients, the pediatric hematology segment added **48** new partner hospitals, and NGS Ig/TCR rearrangement technology products sales grew over **50%**[14](index=14&type=chunk) - The neurology field added **34** new diagnostic projects, **44** new partner referral hospitals, and deepened cooperation with Southern Hospital[14](index=14&type=chunk) - In oncology, **15** new key partners were added, including Peking University Cancer Hospital, with solid tumor large panel testing and solid tumor MRD testing growing over **100%** year-on-year[15](index=15&type=chunk) - The acquisition of Kindstar Medical Guangzhou was completed in January 2025, establishing a comprehensive full-disease course diagnostic system covering solid tumor early screening, early diagnosis, recurrence monitoring, and companion diagnostics[15](index=15&type=chunk)[16](index=16&type=chunk) - **UriFind®** (urothelial carcinoma auxiliary diagnostic reagent kit) sales volume increased by approximately **82%** year-on-year in H1 2025[21](index=21&type=chunk) - The maternal and child specialty team was established to promote growth in pediatric endocrinology referral business[17](index=17&type=chunk) - In cardiovascular diagnostic testing, mass spectrometry platform R&D and testing capabilities improved, with **1** new Class I reagent filing for mass spectrometry testing and **1** new Class II in vitro diagnostic kit approved, and **3** clinical mass spectrometry laboratories co-built[17](index=17&type=chunk) [Scientific Research and Innovation Drive Industry Development](index=10&type=section&id=%E7%A7%91%E7%A0%94%E5%88%9B%E6%96%B0%E9%A9%B1%E5%8A%A8%E8%A1%8C%E4%B8%9A%E5%8F%91%E5%B1%95) In H1 2025, the company significantly increased R&D investment, achieving notable innovations including academic publications, numerous patent applications, and new diagnostic projects, particularly in CAR-T monitoring, leukemia MRD monitoring, and AI-integrated pathology diagnostics - In H1 2025, the Group's R&D department published **33** articles, filed **67** patent applications (**29** of which were authorized), and obtained **24** copyrights[18](index=18&type=chunk) - **56** new R&D diagnostic projects were added, covering molecular biology, flow cytometry, cytogenetics, and pathology diagnostic technologies[18](index=18&type=chunk) - Key developments include CAR-T monitoring and evaluation projects, acute myeloid leukemia MRD monitoring (detection limit improved to **0.1%**), fusion gene quantitative detection (NGS technology for **144** genes), and plans to integrate remote scanning and AI analysis to enhance comprehensive diagnostic capabilities[18](index=18&type=chunk) [Immunome Profiling Products Show Significant Potential](index=10&type=section&id=%E5%85%8D%E7%96%AB%E7%BB%84%E5%BA%93%E4%BA%A7%E5%93%81%E6%BD%9C%E5%8A%9B%E5%87%B8%E6%98%BE) The company's core immunome profiling product, 'LymphoTrack,' continues to expand in hematological malignancy MRD detection, showing significant revenue growth and international quality certification, while health monitoring and immune reconstitution products have deepened market collaborations - The core product **LymphoTrack** (used for hematological malignancy minimal residual disease detection) has covered over **160** institutions in **26** provinces, with revenue growing nearly **30%** compared to H1 2024[19](index=19&type=chunk) - Kindstar Biotech's Ig/TCR project achieved a perfect score in the EuroClonality EQA program, becoming the only laboratory in China to participate and pass with a perfect score[19](index=19&type=chunk) - Health monitoring product **Kangbeice** and immune reconstitution and monitoring product **Fantech** continue to deepen cooperation with renowned enterprises, institutions, and pharmaceutical companies[19](index=19&type=chunk) [Specialized Diagnostic Reagents](index=10&type=section&id=%E7%89%B9%E6%A3%80%E8%AF%95%E5%89%82) The company's specialized diagnostic reagent product line continues to expand, covering NGS capture, multiplex amplification, universal library preparation, single gene mutation, fusion gene, and transplantation series, with significant growth in proprietary product sales and progress in acquired IVD businesses, such as a substantial increase in UriFind® sales - Haixi Bio's product line has developed and transferred over **180** products, covering NGS capture-based, NGS multiplex amplification series, NGS universal library preparation series, single gene mutation detection series, fusion gene detection series, and transplantation series products[20](index=20&type=chunk) - The NGS reagent kits produced by Haixi Bio are compatible with an increasing number of sequencing platforms, and its **74** fusion gene screening projects are at a leading domestic level[20](index=20&type=chunk) - In H1 2025, the Group's proprietary specialized diagnostic reagent business sales increased by over **20%** compared to H1 2024[20](index=20&type=chunk) - **UriFind®** (the first domestically approved reagent kit for auxiliary diagnosis of urothelial carcinoma) completed procurement processes with **11** hospitals and **8** third-party clients, with reagent sales volume increasing by approximately **82%** year-on-year in H1 2024[21](index=21&type=chunk) - The blood-based non-invasive gastric cancer early detection product **Gastromia® (Wei Yijian)** has completed in vitro diagnostic reagent registration clinical research and entered the product registration application phase, with a negative accuracy rate of over **99%**[21](index=21&type=chunk) [Research Services and Contract Research Organization (CRO)](index=11&type=section&id=%E7%A7%91%E7%A0%94%E6%9C%8D%E5%8A%A1%E5%8F%8A%E5%90%88%E7%B4%84%E7%A0%94%E7%A9%B6%E7%B5%84%E7%B9%94%EF%BC%88%E3%80%8CCRO%E3%80%8D%EF%BC%89) Leveraging its R&D innovation and bioinformatics expertise, the company has become a multi-omics research service provider for leading domestic and international biological research institutions and pharmaceutical companies, achieving significant growth in research service revenue and actively expanding into overseas markets and new product lines - Since 2023, the company has been a multi-omics research service provider for domestic and international biological research institutions and pharmaceutical companies, operating **3** PacBio Revio platforms, with **2** serving the domestic market and **1** serving the overseas market[22](index=22&type=chunk) - Fully upgraded to the latest PacBio SPRQ reagents, single-cell output increased by up to **49%**, positioning its total delivery capacity and throughput among the top PacBio service providers nationwide[22](index=22&type=chunk) - The research services segment added nearly **100** new partner hospitals and enterprises in H1, achieving total revenue of nearly **RMB 20 million**[22](index=22&type=chunk) - Preliminary completion of overseas laboratory construction in New Zealand, and domestically, independently developed and

Core Insights - Kangsheng Global (09960.HK) announced that its subsidiary, Wuhan Xino Medical Laboratory, has received CAP (College of American Pathologists) certification [1] Company Summary - Kangsheng Global's subsidiary, Wuhan Xino Medical Laboratory, has achieved a significant milestone by obtaining CAP certification, which is a recognized standard in laboratory quality and performance [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康聖環球基因技術有限公司 呈交日期: 2025年9月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09960 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.00025 | USD | | 500,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 2,000,000,000 | USD | | 0.00025 | USD | | 500,000 | 本月底法定/註冊 ...

Core Viewpoint - 康圣环球 (09960.HK) reported a decline in revenue and profit for the six months ending June 30, 2025, indicating challenges in its operational performance [1] Financial Performance - Revenue for the period was RMB 457 million, a decrease of 3.5% year-on-year [1] - Gross profit amounted to RMB 197 million, reflecting a year-on-year decline of 13.0% [1] - The loss attributable to the company's owners was RMB 36.07 million, compared to a profit of RMB 11.89 million in the same period last year [1] Margin Analysis - The gross margin decreased from 47.7% in the same period of 2024 to 43.0%, a drop of 4.7 percentage points [1] - The decline in gross margin was attributed to reduced revenue and increased fixed operating costs from new laboratories [1]